First Call Research has recommended buying the stock of Surya Roshni with a price target of Rs 76.50.
"On the basis of EV/EBITDA, the stock trades at 4.04 x for FY14E and 3.64 x for FY15E. Price to Book Value of the stock is expected to be at 0.41 x and 0.37 x respectively for FY14E and FY15E. We expect that the company surplus scenario is likely to continue for the next three years, will keep its growth story in the coming quarters also. We recommend 'BUY' in this particular scrip with a target price of Rs 84 for Medium to Long term investment," Firstcall has said in its research report.
Emkay Global has recommended Yes Bank with a price target of Rs 460.
"We are not factoring any capital infusion (given lower valuations) into our numbers for now and believe that the customer assets growth at 20% would fall in line with the RoEs. Stock has underperformed its peers in recent past and currently trades at 1.7x/1.4x FY14/15E ABV respectively. We retain HOLD rating with a target price of Rs 460," Emkay Global has said in its research report.
Firstcall Research has recommended a hold rating on Indoco Remedies with a target of Rs 71.
"Indoco Remedies achieved a turnover of Rs. 1539.80 million for the 1st quarter of the current year 2013-14 as against Rs. 1560.80 millions in the corresponding quarter of the previous year. The company has reported an EBITDA of Rs. 245.20 millions and a net profit of Rs. 91.80 million and 103.50 million reported respectively in the corresponding quarter of the previous year. The company has reported an EPS of Rs. 1.00 for the 1st quarter as against an EPS of Rs. 5.62 in the corresponding quarter of the previous year. The change in the EPS is due to the stock split (Face value) of the company from Rs. 10.00 to Rs.2.00."